Cardiologic prophylaxis for Contrast Induced Nephropathy (CARCIN-trial)

Completed

• Conditions: Contrast-induced-nephropathy; kidney failure; 10046973; 10029149

• Registration Number: NL-OMON43732
• Lead Sponsor: Academisch Medisch Centrum

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 11 June 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 80

Inclusion Criteria

Patient is planned for Contrast enhanced CT and/or TAVI-procedure
eGFR < 60 ml/min/1.73m^2
written informed consent

Exclusion Criteria

M. Kahler / M. Waldenström

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>The level of serum creatinine and eGFR 2-5 days (48-120 hours) after contrast<br /><br>administration compared to pre-contrast baseline serum creatinine. </p><br>

Secondary Outcome Measures

Name	Time	Method
<p>• Occurrence of CIN (Contrast Induced Nefropathy, defined as an increase of<br /><br>serum creatinine >25% or 44.2 µmol/l within 2-5 days according to international<br /><br>definitions for AKI.<br /><br>• Level of increase of NT-proBNP in serum<br /><br>• Self-reported level of dyspnoea using the BORG-CR10 scale compared before and<br /><br>after hydration</p><br>